Clinical and epidemiological aspects of corpus uteri cancer in the context of prevention of recurrent endometrial hyperplasia
- Authors: Klinyshkova T.V.1, Turchaninov D.V.1, Frolova N.B.2
-
Affiliations:
- Omsk State Medical University Ministry of Health of Russia
- Railway Clinical Hospital at the Omsk Passenger Station OAO "RZhD"
- Issue: No 1 (2020)
- Pages: 135-140
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248701
- DOI: https://doi.org/10.18565/aig.2020.1.135-140
- ID: 248701
Cite item
Open Access
Access granted
Abstract
Objective. To analyze trends in the incidence of corpus uteri cancer (CUC) in the Omsk Region in 2002-2018 to prioritize cancer prevention in patients with endometrial hyperplasia (EH). Material and methods. A continuous descriptive observational retrospective epidemiological study of CUC incidence rates was conducted using official statistics. Results. There was a moderate tendency for higher CUC incidence rates in the region (Growth rate (Gr) = +1.8%; p < 0.001) and in the Russian Federation (Gr = +1.7%; p <0.001). The highest proportion was 32.3% of women aged 60-69 years. There was a moderate tendency for increased CUC incidence rates among 30 to 39 year olds and a marked tendency for higher ones in women aged 35-39 years (Gr = +5.6%; p <0.05). A rationale was provided for an integrated approach to managing patients with EH in the context of prevention of the recurrent disease. Conclusion. It was established that the Omsk Region showed a rise in CUC incidence and a tendency for patients with th is disease to become younger. One of the measures to reduce the risk of HE recurrence and progression is the need for a preventive therapy cycle, by taking into account endometrial morphological control.
Keywords
Full Text
About the authors
Tatiana V. Klinyshkova
Omsk State Medical University Ministry of Health of Russia
Email: klin_tatyana@mail.ru
MD, Full Professor, Professor of the Graduate Education Department of obstetrics and gynecology 644043 Russia, Omsk, Lenin Str., 12
Denis V. Turchaninov
Omsk State Medical University Ministry of Health of Russia
Email: omskgsen@yandex.ru
MD, Full Professor, Head of the Department of Hygiene and Nutrition 644043 Russia, Omsk, Lenin Str., 12
Natalia B. Frolova
Railway Clinical Hospital at the Omsk Passenger Station OAO "RZhD"
Email: nbfrolova@yandex.ru
PhD, Head of gynecological Department 644005 Russia, Omsk, Karbysheva str., 41
References
- Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018. 250 e
- World Health Organization: GLOBOCAN 2018. Cancer Today -IARC. https://gco.iarc.fr/today/home
- Думановская М.Р., Чернуха Г.Е., Асатурова А.В., Коган Е.А. Частота выявления и структура гиперплазии эндометрия в различные возрастные периоды. Акушерство и гинекология. 2015; 3: 40-4.
- Orbo A., Vereide A., Arnes M., Pettersen I., Straume B. Levonorgestrel-impregnated intrauterine device as treatment forendometrial hyperplasia: a national multicentre randomised trial. BJOG. 2014; 21(4): 477-86. doi: 10.1111/1471-0528.12499.
- Marnach M.L., Butler K.A., Henry M.R., Hutz C.E., Langstraat C.L., Lohse C.M., Casey P.M. Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia. J Womens Health (Larchmt). 2017; 26(4): 368-73. doi: 10.1089/jwh.2016.5774.
- El Behery M.M., Saleh H.S., Ibrahiem M.A., KamalE.M., Kassem G.A., Mohamed Mel S. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia. Reprod Sci. 2015; 22(3): 329-34. doi: 10.1177/1933719114542014
- Abu Hashim H., Zayed A., Ghayaty E., El Rakhawy M. LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial. J Gynecol Oncol. 2013; 24(2): 128-34. doi: 10.3802/jgo.2013.24.2.128.
- Gallos I.D., Shehmar M., Thangaratinam S., Papapostolou T.K., Coomarasamy A., Gupta J.K. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Аm J Obstet Gynecol. 2010; 203(6): 547.e1-10. doi: 10.1016/j.ajog.2010.07.037
- Gallos I.D., Krishan P., Shehmar M., Ganesan R., Gupta J.K. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Hum Reprod. 2013; 28(11): 2966-71. doi: 10.1093/humrep/det320
- Клинышкова Т.В., Фролова Н.Б., Мозговой С.И. Клинико-морфологическое обоснование оптимизации лечения больных с гиперплазией эндометрия. Российский вестник акушера-гинеколога. 2010; 3: 16-20.
- Чернуха Г.Е., Могиревская О.А., Шигорева Т.В., Грибанова Н.Д. Клиникоморфологические аспекты внутриматочного воздействия левоноргестрела при гиперплазии эндометрия. Акушерство и гинекология. 2011; 4: 56-62.
- Management of Endometrial Hyperplasia. Green-top Guideline No. 67 RCOG/BSGE Joint Guideline | February 2016 https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg_67_endometrial_hyperplasia.pdf
- rbo A., Arnes M., Vereide A.B., Straume B. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens. BJOG. 2016;123(9):1512-9. doi: 10.1111/ 1471-0528.13763.
- Тихомиров А.Л. Обоснование использования комбинированных оральных контрацептивов для профилактики рецидивов типичных гиперплазий эндометрия. Гинекология. 2018; 20(4): 26-8.
- Гиперпластические процессы эндометрия. Гинекология. Национальное руководство. М., 2017. С. 303-308. [Hyperplastic processes of the endometrium. Gynecology. National leadership. M., 2017; 303-308. (in Russian)]
Supplementary files
